118 related articles for article (PubMed ID: 20979530)
1. Targeting the glycoprotein 130 receptor subunit to control pain and inflammation.
Jazayeri JA; Upadhyay A; Vernallis AB; Carroll GJ
J Interferon Cytokine Res; 2010 Dec; 30(12):865-73. PubMed ID: 20979530
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.
Jazayeri JA; Carroll GJ; Vernallis AB
Int Immunopharmacol; 2010 Jan; 10(1):1-8. PubMed ID: 19804846
[TBL] [Abstract][Full Text] [Related]
3. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
6. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
8. gp130: a promising drug target for cancer therapy.
Xu S; Neamati N
Expert Opin Ther Targets; 2013 Nov; 17(11):1303-28. PubMed ID: 24099136
[TBL] [Abstract][Full Text] [Related]
9. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction.
Hilfiker-Kleiner D; Shukla P; Klein G; Schaefer A; Stapel B; Hoch M; Müller W; Scherr M; Theilmeier G; Ernst M; Hilfiker A; Drexler H
Circulation; 2010 Jul; 122(2):145-55. PubMed ID: 20585009
[TBL] [Abstract][Full Text] [Related]
10. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
11. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
[TBL] [Abstract][Full Text] [Related]
12. Targeting gp130 to prevent inflammation and promote insulin action.
Kraakman MJ; Allen TL; Whitham M; Iliades P; Kammoun HL; Estevez E; Lancaster GI; Febbraio MA
Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():170-5. PubMed ID: 24003934
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies.
Wijdenes J; Heinrich PC; Müller-Newen G; Roche C; Gu ZJ; Clément C; Klein B
Eur J Immunol; 1995 Dec; 25(12):3474-81. PubMed ID: 8566040
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding activity in dexamethasone-treated AIDS-associated Kaposi's sarcoma cells: selective synergy between dexamethasone and gp130-related growth factors in Kaposi's sarcoma cell proliferation.
Murakami-Mori K; Mori S; Taga T; Kishimoto T; Nakamura S
J Immunol; 1997 Jun; 158(11):5518-26. PubMed ID: 9164976
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
16. Synthetic mimetics of the gp130 binding site for viral interleukin-6 as inhibitors of the vIL-6-gp130 interaction.
Sudarman E; Bollati-Fogolín M; Hafner M; Müller W; Scheller J; Rose-John S; Eichler J
Chem Biol Drug Des; 2008 May; 71(5):494-500. PubMed ID: 18373551
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.
Gupta D; Orehek S; Turunen J; O'Donovan L; Gait MJ; El-Andaloussi S; Wood MJA
Cells; 2023 Sep; 12(18):. PubMed ID: 37759507
[TBL] [Abstract][Full Text] [Related]
18. Functional properties of extracellular domains of transducer receptor gp130.
Kostjukova MN; Tupitsyn NN
Biochemistry (Mosc); 2011 Apr; 76(4):394-406. PubMed ID: 21585315
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis.
Richards PJ; Nowell MA; Horiuchi S; McLoughlin RM; Fielding CA; Grau S; Yamamoto N; Ehrmann M; Rose-John S; Williams AS; Topley N; Jones SA
Arthritis Rheum; 2006 May; 54(5):1662-72. PubMed ID: 16646038
[TBL] [Abstract][Full Text] [Related]
20. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice.
Kroy DC; Beraza N; Tschaharganeh DF; Sander LE; Erschfeld S; Giebeler A; Liedtke C; Wasmuth HE; Trautwein C; Streetz KL
Hepatology; 2010 Feb; 51(2):463-73. PubMed ID: 19918973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
